But a lacklustre pipeline could stoke the need for deals.
Curiously, the $900m acquisition will not include many of Teneobio’s pipeline projects.
The group’s purchase of Affiris’s Parkinson’s portfolio comes after stumbles from Roche/Prothena and Biogen.
Lilly will soon discover whether its purchase of Dermira was wise.
Axsome and Sanofi face FDA verdicts in depression and Pompe disease respectively, while a Keytruda combo ups the ante in kidney cancer.
The third quarter will see important data for Travere, Radius and Sio Gene, among other small developers.
Promises to act on pharma’s financial toxicity increasingly seem to lack bite, but EQRX promises to follow its words with real action.
Awaiting crucial pivotal data, company reckons its plant-generated Covid-19 vaccine can still make a contribution to the pandemic.
The pivotal trial of Medtronic’s hypertension device came out more than a year ago, yet the company has still not sought approval.